Valuation : SANA AB

Market Cap 1.4B 145M 125M 118M 107M 201M 13.81B 202M 539M 7.03B 543M 531M 22.21B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.4B 145M 125M 118M 107M 201M 13.81B 202M 539M 7.03B 543M 531M 22.21B EV / Sales 2026 *
13.6x
EV / Sales 2027 * 6.7x
Free-Float
90.64%
Yield 2026 *
-
Yield 2027 * -
1 day-4.69%
1 week-14.06%
Current month-11.28%
1 month-25.26%
3 months-22.22%
6 months-34.77%
Current year-52.12%
1 week 10.09
Extreme 10.09
11.94
1 month 10.09
Extreme 10.09
13.87
Current year 10.09
Extreme 10.09
28.3
1 year 10.09
Extreme 10.09
28.3
3 years 1.74
Extreme 1.736
28.3
5 years 1.57
Extreme 1.572
28.3
10 years 1.57
Extreme 1.572
55
Manager TitleAgeSince
Chief Operating Officer 54 01/03/2025
Chief Executive Officer 66 30/04/2022
Chief Tech/Sci/R&D Officer 68 01/01/2014
Director TitleAgeSince
Chairman 71 30/04/2022
Director/Board Member 68 01/01/2015
Director/Board Member 46 19/01/2018
Date Insider Type Main position Quantity % Market Cap. Importance
09/09/26 Buy

Chairman

50,000 0.0362%
01/09/26 Buy

Founder

9,000 0.0065%
28/08/26 Buy

Chief Financial Officer

5,000 0.0036%
Change 5-day change 1-year change 3-year change Capi.($)
-4.69%-14.06%-12.65%+56.15% 152M
-2.11%-1.68%+44.52%+95.15% 68.24B
-0.23%-4.45%+30.39%+73.64% 62.23B
+1.67%+2.47%-11.23%+388.34% 27.8B
-1.05%-4.43%+30.56%+10.07% 24.86B
+0.34%-6.78%-7.27%-17.99% 24.22B
+0.43%-3.37%+14.85%-19.29% 19.36B
-3.03%-2.29%+185.12%+334.07% 17.28B
-1.94%-4.94%-5.29%+495.65% 14.46B
-2.28%-4.90%+43.64%+155.21% 14.23B
Average -1.29%-4.40%+31.26%+157.10% 27.28B
Weighted average by Cap. -0.86%-3.31%+33.83%+133.67%

Financials

2026 *2027 *
Net sales 103M 10.64M 9.17M 8.68M 7.87M 14.76M 1.02B 14.84M 39.65M 517M 39.96M 39.08M 1.63B 209M 21.59M 18.6M 17.61M 15.97M 29.95M 2.06B 30.1M 80.45M 1.05B 81.09M 79.31M 3.32B
Net income - -
Net Debt - -
Logo SANA AB
Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The Company is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.
Employees
44
Date Price Change Volume
11/09/26 SEK 10.15 -4.69% 409,623
10/09/26 SEK 10.65 -1.11% 277,163
09/09/26 SEK 10.77 -1.28% 602,874
08/09/26 SEK 10.91 -1.36% 1,000,785
07/09/26 SEK 11.06 -6.35% 576,203

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SANION Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!